Contrast-induced nephropathy in the context of PCI, a lot more frequent in women

Original title: Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevatio myocardial infarction. Reference: Stefano Lucreziotti, et al. International Journal of Cardiology 2014;174:37-42

 

Primary PCI has been demonstrated beneficial. However, it is associated to greater contrast-induced nephropathy (CIN) with increased in hospital and long term morbidity and mortality. In addition, several reports have shown women evolve worse after this complication, compared to men. This study analyzed post primary PCI serum creatinine increase in 323 patients.

Baseline was defined as 1.2 mg/dl and CIN was defined as an increase in serum creatinine (≥25% or ≥0.5mg/dl) from baseline during the first 72 hrs. 63% of the general population had a Mehran risk score (MRS) ≥6. Compared to men, women were of older age, had a higher MRS, lower renal function and longer symptom to reperfusion time.  CIN predictors included female gender, older age, reduced LV ejection function, preexisting kidney failure and high MRS. The multivariable analysis associated female gender and reduced LV ejection fraction to CIN.

In-hospital mortality was higher in patients developing CIN (20.4% vs. 2.6%;  p<0.001), in women (9.3% vs. 3.5%; p=0.02) and in patients with reduced ventricular function (36.7% vs. 2%; p=0.001). The study also divided the population in two groups according to MRS 6, and showed higher mortality in patients with >6 (1.9% vs. 11.3% p<0.001).

Conclusion

In primary PCI, female gender and reduced LVEF are associated to contrast induced nephropathy. This complication is an independent predictor of in-hospital and long term mortality. 

Editorial Comment

This analysis shows that, in patients undergoing primary PCI, female gender is an independent predictor of CIN, associated to poor clinical outcomes. This may be due to the fact that females were of older age, had a higher MRS, lower renal function and longer symptom to reperfusion time. 

Courtesy of Dr. Carlos Fava
Interventional Cardiologist
Favaloro Foundation
Buenos  Aires

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...